Merck KGaA’s $6.7 B Acquisition of Terns Pharmaceuticals

Merck KGaA today announced a definitive agreement to acquire Terns Pharmaceuticals, an oncology‑focused specialty firm, for approximately $6.7 billion in cash. The transaction, which is slated to close in the second quarter, represents a strategic effort by Merck to strengthen its cancer portfolio in anticipation of the impending expiration of the key patent on its flagship immuno‑oncology drug, Keytruda.

Transaction Structure and Financial Impact

  • Purchase Price: $53 per Terns share, paid in cash.
  • Estimated Accounting Charge: $5.8 billion, translating to roughly $2.35 per Merck share.
  • Financial Statement Effect: The charge will be reflected in Merck’s upcoming second‑quarter and full‑year reports, with a corresponding impact on net income and earnings per share.

The acquisition is expected to bring new therapies for blood cancers—particularly chronic myeloid leukemia—into Merck’s pipeline, thereby mitigating potential revenue losses when the Keytruda patent lapses. The deal also complements Merck’s recent purchase of Verona Pharma, a respiratory‑disease specialist, underscoring a broader strategy of portfolio diversification across therapeutic areas.

Strategic Rationale

  • Patent Lapse Mitigation: Keytruda’s patent expiration threatens to open the market to biosimilar competition. By adding Terns’ oncology assets, Merck aims to sustain its market leadership and revenue streams.
  • Blood Cancer Focus: Terns’ pipeline includes promising agents for chronic myeloid leukemia, a field in which Merck already has a presence. The synergy between existing and new assets could accelerate clinical development timelines.
  • Cross‑Sector Expansion: The Verona acquisition signals Merck’s intent to broaden its therapeutic footprint beyond oncology, potentially creating new cross‑selling opportunities and leveraging shared R&D capabilities.

Market and Economic Context

The pharmaceutical industry is currently navigating a landscape marked by patent expirations, increasing regulatory scrutiny, and intense competition from both large multinational firms and nimble biotech newcomers. Merck’s move to acquire Terns demonstrates a proactive approach to securing future growth assets while managing the risks associated with key intellectual property milestones.

The broader German chemical and pharmaceutical sector has also taken steps to address macroeconomic pressures. A recent wage agreement, negotiated in Bad Breisig between the IG BCE union and the BAVC employer group, will introduce modest salary increases in two stages—January 2027 and January 2028—alongside a contribution from employers to a job‑security fund. Although this accord does not directly affect Merck, it reflects the sector’s efforts to maintain employment stability amid rising energy costs and global market pressures.

Competitive Positioning

Merck’s acquisition of Terns places it in a stronger position relative to competitors such as Roche and Pfizer, who are also bolstering their oncology portfolios through strategic deals and internal development. By integrating Terns’ specialized expertise and product candidates, Merck can enhance its value proposition to oncologists and payers alike.

Conclusion

Merck KGaA’s $6.7 billion purchase of Terns Pharmaceuticals is a calculated move designed to secure its oncology pipeline as key patents expire and to broaden its therapeutic reach. The transaction underscores a broader industry trend of consolidation and portfolio diversification, driven by patent dynamics, competitive pressures, and the need for sustained innovation across therapeutic areas.